Why Xenon Pharmaceuticals Inc.’s (XENE) Stock Is Up 6.00%
As of Thursday, October 01, Xenon Pharmaceuticals Inc.’s XENE share price has surged by 6.00%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company’s Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Commentary & Analysis
Why Xenon Pharmaceuticals Inc.’s (XENE) Stock Is Down 6.37%
As of Wednesday, September 23, Xenon Pharmaceuticals Inc.’s XENE share price has dipped by 6.37%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Xenon Pharmaceuticals Inc.’s (XENE) Stock Is Down 27.06%
As of Friday, September 18, Xenon Pharmaceuticals Inc.’s XENE share price has dipped by 27.06%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Xenon Pharmaceuticals Inc.’s (XENE) Stock Is Down 30.64%
As of Friday, September 18, Xenon Pharmaceuticals Inc.’s XENE share price has dipped by 30.64%, which has investors questioning if this is right time to buy.Jenna Brashear
Which Is a Better Investment, AnaptysBio, Inc. or Xenon Pharmaceuticals Inc. Stock?
Learn more about whether AnaptysBio, Inc. or Xenon Pharmaceuticals Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Financial Summary
| Share Statistics | XENE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,793.2 | $219.9 | 64% |
|
| Shares Out (Mil) | 99.6 | 54.1 | 62% |
|
| Institutional Ownership | 99.8% | 92.9% | 94% |
|
| Float (Mil) | 90.9 | 41.4 | 58% |
|
| Beta | 0.62 | 0.95 | 36% |
|
| Avg Daily Volume (000s) | 1,380 | 522 | 73% |
|
| Price Change (52-week) |
1.3% | 44.7% | 52% |
|
| Growth | XENE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (25.3%) | 13.2% | 2% |
|
| Net Income (5yr) | (64.4%) | (10.1%) | 5% |
|
| EPS (5yr) | (40.4%) | 15.8% | 5 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 4.9% | (15.7%) | 67% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 13 | 13 | |
| Current EPS | ($1.145) | ($4.627) | ($4.701) | |
| Month Ago EPS | ($1.150) | ($4.628) | ($4.714) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 3 | 0 | 1 | |
| Three Months Ago EPS | ($1.158) | ($4.610) | ($4.857) | |
| Year/Year Chg | 3.0% | 6.0% | (13.6%) | |
| Financials | XENE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($409) | ($44) | 3% |
|
| EPS (TTM) | ($4.726) | ($1.500) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($338) | ($35) | 3% |
|
| Net Cash Flow (TTM) (Mil) | ($16) | $0 | 29% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $4 | 25% |
|
| Enterprise Value (Q1) (Mil) | $4,315 | $166 | 61% |
|
| Valuation | XENE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.05 | 2.06 | 69% |
|
| P/E | na | 16.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | XENE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (61.0%) | na |
|
| ROA | (41.5%) | (47.5%) | 13% |
|
| ROE | (43.6%) | (52.7%) | 17% |
|
| Liabilities to Assets | 4.1% | 29.6% | 2% |
|
| F-Score | 3 | 3 | 18% |
|
Xenon Pharmaceuticals Inc. did not pass any screens on 11/6/2026.
